

Figure 1 shows the results of the analysis. The first row of the table shows the results for the full sample. The second row shows the results for the subsample of firms that are not in the top 100. The third row shows the results for the subsample of firms that are in the top 100. The fourth row shows the results for the subsample of firms that are in the top 100 and are also in the top 100 of the industry. The fifth row shows the results for the subsample of firms that are in the top 100 and are also in the top 100 of the industry and are also in the top 100 of the industry. The sixth row shows the results for the subsample of firms that are in the top 100 and are also in the top 100 of the industry and are also in the top 100 of the industry. The seventh row shows the results for the subsample of firms that are in the top 100 and are also in the top 100 of the industry and are also in the top 100 of the industry. The eighth row shows the results for the subsample of firms that are in the top 100 and are also in the top 100 of the industry and are also in the top 100 of the industry. The ninth row shows the results for the subsample of firms that are in the top 100 and are also in the top 100 of the industry and are also in the top 100 of the industry. The tenth row shows the results for the subsample of firms that are in the top 100 and are also in the top 100 of the industry and are also in the top 100 of the industry.

The present invention is, for example, a therapeutic or preventive agent for hepatitis characterized in that it comprises a complex of a drug carrier consisting essentially of 2-O-(2-diethylaminoethyl)-carbamoyl-1,3-O-dioleoylglycerol and a phospholipid with poly(I).poly(C).